GC Therapeutics
Muhan Li is a Principal Research Associate at GC Therapeutics since January 2024, bringing extensive experience in assay development and regenerative medicine. Previously, Muhan worked as a Senior Associate Scientist at ElevateBio, where responsibilities included collaborating on an iPSC-derived T cell project and designing Flow Cytometry panels. Muhan's earlier roles include Associate Scientist II and Research Associate II at CRISPR Therapeutics, focusing on flow cytometry optimization for immune cells, and a COVID-19 testing Laboratory Technician at Medical Diagnostic Laboratories. Muhan also has research experience at the University of Pennsylvania as a Graduate Student Researcher in bioinformatics and at the China Academy of Science studying Arabidopsis. Muhan holds a Master’s degree in Biotechnology from the University of Pennsylvania and a Bachelor of Science in Cell/Cellular and Molecular Biology from the University of Washington.
GC Therapeutics
1 followers
GC Therapeutics Inc. (GCTx) uses synthetic biology to program patient-derived stem cells into any cell type with best-in-class efficiency (up to 10X), speed (up to 100X) and scalability. We dictate cells fates in a single step and have validated cells for many applications. We have also developed SuperCells™ by tailoring cells for specific diseases. The core technology of GCTx was conceived, invented and perfected in Professor George Church’s lab at Harvard Medical School. We are a group of passionate biologists and tissue engineers whose goal is to bring this breakthrough approach to patients.